Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ifabotuzumab (KB004), an IgG1κ antibody, specifically binds to EphA3 (K D =610 pM), inducing tumor cell apoptosis, activating antibody-dependent cell-mediated cytotoxicity (ADCC), and damaging tumor vasculature. Additionally, Ifabotuzumab effectively reduces CCR10+ cells in human idiopathic pulmonary fibrosis (IPF) and ameliorates pulmonary fibrosis, demonstrating its therapeutic potential [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Ifabotuzumab (KB004), an IgG1κ antibody, specifically binds to EphA3 (K D =610 pM), inducing tumor cell apoptosis, activating antibody-dependent cell-mediated cytotoxicity (ADCC), and damaging tumor vasculature. Additionally, Ifabotuzumab effectively reduces CCR10+ cells in human idiopathic pulmonary fibrosis (IPF) and ameliorates pulmonary fibrosis, demonstrating its therapeutic potential [1] [2]. |
Molecular Weight | N/A |
CAS No. | 2147698-66-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ifabotuzumab 2147698-66-4 inhibitor inhibit